LTB4R2 and hepatocellular carcinoma: The model-1 organoid grew 160% faster than model-2 and showed more conspicuous growth inhibition by LTB4R2 antagonism or KD as compared to model 2 (Fig. 4e), suggesting the therapeutic potential of targeting the 12-HHTrE-LTB4R2 pathway for growth inhibition of HCC.